Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1 study, targeted for 2025...

Kaida BioPharma Launches Social Media Channels Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...

Kaida BioPharma to Present at the Virtual Investor Pitch Conference Live webcast on Monday, June 17th at 9:00 AM ET FORT LAUDERDALE, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma company dedicated to...

Ovarian Cancer Treatment Market To Reach USD 18.3 Billion By 2031. By TMR Wilmington, Delaware, United States, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -  The global ovarian cancer treatment market was estimated to have acquired US$ 5.1 billion...

Ovarian Cancer Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsight Los Angeles, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ovarian Cancer Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsight Around 100+ key companies are developing therapies for...